FIGURE 3.

Relationship between LOX and LOXL2 mRNA expression levels and patients’ survival and clinicopathological characteristics in KIRC using the UALCAN. A, Over‐expression of LOX significantly correlated with poor disease‐specific survival (DSS) and progression‐free survival (PFS) in KIRC. B, Upregulated LOXL2 also predicted poor DSS and PFS in KIRC. D‐F, higher mRNA expression of LOX and LOXL2 were significantly correlated with tumor grade, individual cancer stages and nodal metastasis status in KIRC, respectively. G,H, over‐expressed protein expression levels of LOX and LOXL2 were significantly closed to tumor grade and individual cancer stages. *p < .05; **p < .01; ***p < .001